Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial
Authors
Chan, W. Y.Counsell, N.
de Tute, R.
De-Silva, D.
Phillips, Elizabeth H
Cavenagh, J.
Adedayo, T.
Braganca, N.
Roddie, C.
Streetly, M.
Schey, S.
Koh, M. B. C.
Crowe, J.
Morris, T. C.
Cook, G.
Clifton-Hadley, L.
Rabin, N.
Owen, R. G.
Popat, R.
Yong, K. L.
Affiliation
University College London Hospitals NHS Foundation Trust, London, UKIssue Date
2021
Metadata
Show full item recordCitation
Chan WY, Counsell N, Tute R, De?Silva D, Phillips EH, Cavenagh J, et al. Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial. British Journal of Haematology. Wiley; 2021.Journal
British Journal of HaematologyDOI
10.1111/bjh.17903PubMed ID
34636043Additional Links
https://dx.doi.org/10.1111/bjh.17903Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1111/bjh.17903
Scopus Count
Collections
Related articles
- RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.
- Authors: Chapman MA, Sive J, Ambrose J, Roddie C, Counsell N, Lach A, Abbasian M, Popat R, Cavenagh JD, Oakervee H, Streetly MJ, Schey S, Koh M, Willis F, Virchis AE, Crowe J, Quinn MF, Cook G, Crawley CR, Pratt G, Cook M, Braganza N, Adedayo T, Smith P, Clifton-Hadley L, Owen RG, Sonneveld P, Keats JJ, Herrero J, Yong K
- Issue date: 2018 Nov 15
- CXCR4 expression of multiple myeloma as a dynamic process: influence of therapeutic agents.
- Authors: Bögelein A, Stolzenburg A, Eiring P, Lückerath K, Munawar U, Werner R, Schirbel A, Samnick S, Kortüm KM, Sauer M, Lapa C, Buck AK
- Issue date: 2022 Oct
- Evaluation of serum glucose-regulated protein 78 (GRP78) as a biomarker of treatment response to bortezomib-based induction regimen in multiple myeloma: A cross-sectional pilot study.
- Authors: Ramachandran SS, Gupta P, Kumar L, Gupta R, Goel L, Kumar VL, Gupta YK
- Issue date: 2022 Dec
- Response-adapted approach in newly diagnosed myeloma: when less is at least equal.
- Authors: Manasanch EE, Gertz MA
- Issue date: 2022 Sep
- Chalazion in a patient with multiple myeloma treated with bortezomib.
- Authors: Ghimire B, Hamajima Y, Carbajal-Carballo L, Anusim N
- Issue date: 2022 Dec 7